{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:41:37Z","timestamp":1787755297474,"version":"build-2784847793"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    <jats:list list-type=\"plain\">\n                      <jats:list-item>\n                        <jats:p>\u00bb A small yet growing subset of total joint arthroplasty (TJA) candidates are diagnosed with the hepatitis C virus (HCV), which is a known risk factor for periprosthetic joint infections. Given the poor outcomes associated with TJA infection, we recommend that candidates with HCV receive treatment prior to elective TJA.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\u00bb Interferon and ribavirin have historically been the standard treatment regimen for the management of HCV; however, adverse events and an inconsistent viral response have limited the efficacy of these therapies. The advent of direct-acting antivirals has resolved many of the issues associated with interferon and ribavirin regimens.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\u00bb Despite the success of direct-acting antivirals, there are still barriers to seeking treatment for TJA candidates with HCV. Many patients are faced with financial burdens, as insurance coverage of direct-acting antiviral therapies is inconsistent and varies by the patient\u2019s state of residence and specific treatment regimen.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\u00bb TJA candidates with HCV present health-care providers with a unique set of challenges, often encompassing economic, psychosocial, and complex medical concerns. Multidisciplinary care teams can be beneficial when caring for and optimizing this patient cohort.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\u00bb Management of HCV prior to elective TJA is associated with higher up-front costs but ultimately reduces long-term patient morbidity as well as associated direct and indirect health-care expenditures.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>","DOI":"10.2106\/jbjs.rvw.20.00223","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T15:00:13Z","timestamp":1636556413000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Perioperative Management of Hepatitis C in Patients Undergoing Total Joint Arthroplasty"],"prefix":"10.2106","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4474-7240","authenticated-orcid":false,"given":"Phillip E.","family":"Ross","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Albany Medical Center, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4624-3556","authenticated-orcid":false,"given":"Joseph R.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Albany Medical Center, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey M.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Albany Medical Center, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-9894","authenticated-orcid":false,"given":"Afshin A.","family":"Anoushiravani","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Albany Medical Center, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-0210","authenticated-orcid":false,"given":"Matthew R.","family":"DiCaprio","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Albany Medical Center, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,11]]},"reference":[{"issue":"9","key":"r1-20240731","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"r2-20240731","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"r3-20240731","first-page":"167","article-title":"Prevalence of hepatitis B and hepatitis C in an orthopaedics and traumatology ward","volume":"86","author":"Villani","year":"2001","journal-title":"Chir Organi Mov"},{"issue":"23","key":"r4-20240731","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.2106\/JBJS.O.00183","article-title":"The impact of hepatitis C on short-term outcomes of total joint arthroplasty","volume":"97","author":"Issa","year":"2015","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"r5-20240731","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.arth.2013.03.023","article-title":"Fibrosis in hepatitis C patients predicts complications after elective total joint arthroplasty","volume":"29","author":"Orozco","year":"2014","journal-title":"J Arthroplasty"},{"issue":"7S","key":"r6-20240731","article-title":"Short and long-term postoperative complications following total joint arthroplasty in patients with human immunodeficiency virus, hepatitis B, or hepatitis C","volume":"33","author":"Kildow","year":"2018","journal-title":". J Arthroplasty."},{"issue":"12","key":"r7-20240731","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.5435\/JAAOS-D-16-00920","article-title":"Complication rates after total hip and knee arthroplasty in patients with hepatitis C compared with matched control patients","volume":"25","author":"Cancienne","year":"2017","journal-title":"J Am Acad Orthop Surg"},{"issue":"9","key":"r8-20240731","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00402-017-2742-7","article-title":"The impact of hepatitis C virus infection on 90-day outcomes following major orthopaedic surgery: a propensity-matched analysis","volume":"137","author":"Chowdhury","year":"2017","journal-title":"Arch Orthop Trauma Surg"},{"issue":"1","key":"r9-20240731","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.arth.2018.09.036","article-title":"Treatment for chronic hepatitis C prior to total hip arthroplasty significantly reduces periprosthetic joint infection","volume":"34","author":"Bedair","year":"2019","journal-title":"J Arthroplasty"},{"issue":"6","key":"r10-20240731","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1302\/0301-620X.101B6.BJJ-2018-0723.R3","article-title":"The preoperative management of hepatitis C may improve the outcome after total knee arthroplasty","volume":"101-B","author":"Schwarzkopf","year":"2019","journal-title":"Bone Joint J"},{"issue":"Suppl 1","key":"r11-20240731","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0168-8278(99)80369-9","article-title":"Natural history of hepatitis C","volume":"31","author":"Alberti","year":"1999","journal-title":"J Hepatol"},{"issue":"7","key":"r12-20240731","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s11999-017-5333-6","article-title":"What is the long-term economic societal effect of periprosthetic infections after THA? A Markov analysis","volume":"475","author":"Parisi","year":"2017","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"r13-20240731","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11999-013-3034-3","article-title":"Bundled payments in total joint arthroplasty: targeting opportunities for quality improvement and cost reduction knee","volume":"472","author":"Bozic","year":"2014","journal-title":"Clin Orthop Relat Res"},{"issue":"9","key":"r14-20240731","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1365-2036.2010.04460.x","article-title":"Barriers to accessing care in patients with chronic hepatitis C: the impact of depression","volume":"32","author":"Evon","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"r15-20240731","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1758-2652-14-22","article-title":"Hepatitis C in HIV-infected individuals: cure and control, right now","volume":"14","author":"Thomas","year":"2011","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"r16-20240731","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.amjmed.2005.05.029","article-title":"What do patients consider when making decisions about treatment for hepatitis C?","volume":"118","author":"Fraenkel","year":"2005","journal-title":"Am J Med"},{"issue":"3","key":"r17-20240731","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00004836-200603000-00009","article-title":"Social stigmatization and hepatitis C virus infection","volume":"40","author":"Zacks","year":"2006","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"r18-20240731","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1046\/j.1525-1497.2003.20826.x","article-title":"\u201cThey treated me like a leper\u201d. Stigmatization and the quality of life of patients with hepatitis C","volume":"18","author":"Zickmund","year":"2003","journal-title":"J Gen Intern Med"},{"issue":"3","key":"r20-20240731","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1042\/CS20060171","article-title":"Immunopathogenesis in hepatitis C virus cirrhosis","volume":"112","author":"Spengler","year":"2007","journal-title":"Clin Sci (Lond)."},{"issue":"1","key":"r21-20240731","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/0974-777X.52979","article-title":"Association between hepatitis C and hepatocellular carcinoma","volume":"1","author":"de Oliveria Andrade","year":"2009","journal-title":"J Glob Infect Dis"},{"issue":"1","key":"r22-20240731","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"7","key":"r23-20240731","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM199302183280703","article-title":"Membranoproliferative glomerulonephritis associated with hepatitis C virus infection","volume":"328","author":"Johnson","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"r24-20240731","first-page":"381","article-title":"Thrombocytopenia in chronic hepatitis C","volume":"19","author":"Olariu","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"issue":"3","key":"r25-20240731","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00000441-200303000-00006","article-title":"Extrahepatic manifestations of hepatitis C infection","volume":"325","author":"Mayo","year":"2003","journal-title":"Am J Med Sci"},{"issue":"8","key":"r26-20240731","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ki.2009.247","article-title":"Hepatitis C virus-induced cryoglobulinemia","volume":"76","author":"Charles","year":"2009","journal-title":"Kidney Int"},{"issue":"13","key":"r27-20240731","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"r28-20240731","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1053\/j.gastro.2013.10.029","article-title":"The efficacy, limitations, and outcomes of our current interferon-based therapies for hepatitis C","volume":"145","author":"Kwo","year":"2013","journal-title":"Gastroenterology"},{"issue":"9","key":"r29-20240731","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"issue":"11","key":"r30-20240731","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"r31-20240731","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3748\/wjg.v22.i4.1421","article-title":"New approaches in the treatment of hepatitis C","volume":"22","author":"Gonz\u00e1lez-Grande","year":"2016","journal-title":"World J Gastroenterol"},{"key":"r32-20240731","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-015-0748-8","article-title":"Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits","volume":"15","author":"Smith-Palmer","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"3","key":"r33-20240731","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/1756283X10363055","article-title":"New direct-acting antivirals in the development for hepatitis C virus infection","volume":"3","author":"Pockros","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"issue":"35","key":"r34-20240731","doi-asserted-by":"crossref","first-page":"13038","DOI":"10.1073\/pnas.0405152101","article-title":"Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication","volume":"101","author":"Evans","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"r35-20240731","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000032","article-title":"Regulation of hepatitis C virion production via phosphorylation of the NS5A protein","volume":"4","author":"Tellinghuisen","year":"2008","journal-title":"PLoS Pathog"},{"issue":"9916","key":"r36-20240731","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"r37-20240731","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"12","key":"r38-20240731","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1016\/j.arth.2019.06.058","article-title":"Undetectable hepatitis C viral load is associated with improved outcomes following total joint arthroplasty","volume":"34","author":"Novikov","year":"2019","journal-title":"J Arthroplasty"},{"issue":"12","key":"r39-20240731","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081355","article-title":"North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"r40-20240731","article-title":"Coinfection with hepatitis C and HIV is a risk factor for poor outcomes after total knee arthroplasty","volume":"2","author":"Mahure","year":"2017","journal-title":"JB JS Open Access"},{"issue":"4","key":"r41-20240731","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"PHOTON-1 Investigators. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"issue":"12","key":"r42-20240731","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jama.2015.1373","article-title":"Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection","volume":"313","author":"Osinusi","year":"2015","journal-title":"JAMA"},{"issue":"Suppl 2","key":"r43-20240731","doi-asserted-by":"crossref","first-page":"S643","DOI":"10.1016\/S0168-8278(15)31022-9","article-title":"P0819 : Simeprevir and sofosbuvir with modified doses of ribavirin (RBV) therapy on telaprevir experienced co infected (with HIV) cirrhotics with chronic hepatitis C (CHC). A randomized open label clinical pilot study: Stop C","volume":"62","author":"Basu","year":"2015","journal-title":"J Hepatol"},{"issue":"S1","key":"r44-20240731","first-page":"295A","article-title":"Sofosbuvir and ribavirin therapy for the treatment of HIV\/HCV coinfected patients with HCV GT1-4 infection: the PHOTON-1 and 2 trials","volume":"60","author":"Rockstroh","year":"2014","journal-title":"Hepatology"},{"issue":"12","key":"r45-20240731","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/cid\/cix111","article-title":"Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus\/hepatitis C virus genotype 1-coinfected patients treated in routine practice","volume":"64","author":"Bhattacharya","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"r46-20240731","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.29814","article-title":"All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus\/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings","volume":"68","author":"Berenguer","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"r47-20240731","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"issue":"9","key":"r48-20240731","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/01.mcg.0000177258.95562.43","article-title":"High rates of uninsured among HCV-positive individuals","volume":"39","author":"Ong","year":"2005","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"r49-20240731","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s10620-006-9579-1","article-title":"Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time?","volume":"52","author":"Khokhar","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"5","key":"r50-20240731","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1046\/j.1365-2893.2001.00310.x","article-title":"Management of hepatitis C patients by primary care physicians in the USA: results of a national survey","volume":"8","author":"Shehab","year":"2001","journal-title":"J Viral Hepat"},{"issue":"5","key":"r51-20240731","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2893.2009.01080.x","article-title":"Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents","volume":"16","author":"Grebely","year":"2009","journal-title":"J Viral Hepat"},{"issue":"3","key":"r52-20240731","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1572-0241.2003.07331.x","article-title":"Identification and management of hepatitis C patients in primary care clinics","volume":"98","author":"Shehab","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"r53-20240731","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1572-0241.2007.01433_4.x","article-title":"A balancing view: we cannot do it alone","volume":"102","author":"Shiffman","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"r54-20240731","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11999-009-0945-0","article-title":"The epidemiology of revision total knee arthroplasty in the United States","volume":"468","author":"Bozic","year":"2010","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"r55-20240731","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2106\/JBJS.H.00155","article-title":"The epidemiology of revision total hip arthroplasty in the United States","volume":"91","author":"Bozic","year":"2009","journal-title":"J Bone Joint Surg Am"},{"issue":"2","key":"r56-20240731","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00264-010-1144-z","article-title":"Infection in total hip replacement: meta-analysis","volume":"35","author":"Senthi","year":"2011","journal-title":"Int Orthop"},{"issue":"9","key":"r57-20240731","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3928\/01477447-20100722-42","article-title":"Periprosthetic joint infection: treatment options","volume":"33","author":"Parvizi","year":"2010","journal-title":"Orthopedics"},{"issue":"5","key":"r58-20240731","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1586\/14737167.2015.1076337","article-title":"The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C","volume":"15","author":"Bickerstaff","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"r59-20240731","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002032","article-title":"Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis","volume":"13","author":"Iyengar","year":"2016","journal-title":"PLoS Med"},{"issue":"6","key":"r60-20240731","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.arth.2017.02.011","article-title":"Gainsharing strategies, physician champions, getting physician buy in","volume":"32","author":"Anoushiravani","year":"2017","journal-title":"J Arthroplasty"},{"issue":"3","key":"r61-20240731","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/j.sart.2016.10.002","article-title":"Alternative payment models: from bundled payments for care improvement and comprehensive care for joint replacement to the future?","volume":"27","author":"Anoushiravani","year":"2016","journal-title":"Semin Arthroplasty"},{"issue":"8","key":"r62-20240731","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.arth.2017.03.027","article-title":"Effect of bundled payments and health care reform as alternative payment models in total joint arthroplasty: a clinical review","volume":"32","author":"Siddiqi","year":"2017","journal-title":"J Arthroplasty"},{"issue":"2","key":"r63-20240731","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.26201","article-title":"Review at a multidisciplinary tumor board impacts critical management decisions of pediatric patients with cancer","volume":"64","author":"Thenappan","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"r64-20240731","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.14694\/EdBook_AM.2014.34.e461","article-title":"Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide","volume":"34","author":"El Saghir","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"r65-20240731","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jvs.2019.08.244","article-title":"A systematic review of multidisciplinary teams to reduce major amputations for patients with diabetic foot ulcers","volume":"71","author":"Musuuza","year":"2020","journal-title":"J Vasc Surg"},{"issue":"12","key":"r66-20240731","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1111\/j.1532-5415.2009.02571.x","article-title":"Successful models of comprehensive care for older adults with chronic conditions: evidence for the Institute of Medicine\u2019s \u201cRetooling for an Aging America\u201d report","volume":"57","author":"Boult","year":"2009","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"r67-20240731","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.artd.2015.07.001","article-title":"Total joint arthroplasty in patients with chronic infectious liver disease","volume":"2","author":"Truntzer","year":"2015","journal-title":"Arthroplast Today"},{"issue":"RR-4","key":"r68-20240731","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965","volume":"61","author":"Smith","year":"2012","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"r69-20240731","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7326\/0003-4819-159-5-201309030-00672","article-title":"Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement","volume":"159","author":"Moyer","year":"2013","journal-title":"Ann Intern Med"}],"container-title":["JBJS Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.RVW.20.00223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:40:44Z","timestamp":1787751644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.RVW.20.00223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":68,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2106\/jbjs.rvw.20.00223","relation":{},"ISSN":["2329-9185"],"issn-type":[{"value":"2329-9185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}